For the Inventor, By the Inventor

Enter assignee name

Berkeley, CA, United States of America

Xoma Corporation

USPTO Granted Patents = 142

CIPO Patents = 5

EPO Patents = 7

Forward Citations = 4,462

Loading Chart...

Loading Chart...

76 inventors (with patents filed for the assignee):

Roger G Little, Ii (25 out of 36 patents)

Stephen Fitzhugh Carroll (24 out of 30 patents)

Arnold H Horwitz (23 out of 49 patents)

4. Marc D Better (20 out of 29 patents)

5. Lewis H Lambert, Jr (16 out of 16 patents)

6. Patrick J Scannon (14 out of 30 patents)

7. Mark Leslie White (13 out of 33 patents)

8. Lynn S Grinna (13 out of 15 patents)

9. Randy R Robinson (13 out of 18 patents)

10. William Steve Ammons (11 out of 11 patents)

11. Shau-Ping Lei (11 out of 14 patents)

12. Gary L Wilcox (11 out of 14 patents)

13. Georgia Theofan (10 out of 12 patents)

14. Alvin Y Liu (10 out of 14 patents)

15. Gary M Studnicka (9 out of 11 patents)

Core Competencies:

Bactericidal/Permeability-Increasing Protein

Therapeutic Compositions

Anti-Fungal Peptides

Anti-Chlamydial Methods

Mycobacterial Diseases

Lipopolysaccharide Binding Protein

Immunotoxins

Biologically Active Peptides

Antithrombotic Materials

Recombinant Microbial Production

Gram-Negative Bacterial Infection

Fusion Proteins

142 patents: Sort by Forward Citations

1. 7081334 - Method for quantifying LBP in body fluids (2006-07-25),

2. 6849598 - Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products (2005-02-01),

3. 6828418 - Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same (2004-12-07),

4. 6767893 - Method of treating conditions associated with intestinal ischemia/reperfusion (2004-07-27),

5. 6759203 - Method for quantifying BPI in body fluids (2004-07-06),

6. 6686332 - Method of treating depressed reticuloendothelial system function (2004-02-03),

7. 6664231 - Anti-fungal peptides (2003-12-16),

8. 6620785 - Treatment of Mycobacterial diseases by administration of bactericidal/permeability-increasing protein products (2003-09-16),

9. 6599881 - Antithrombotic materials and methods (2003-07-29),

10. 6599880 - Bactericidal/permeability-increasing protein (BPI) deletion analogs (2003-07-29),

11. 6596691 - Therapeutic uses of BPI protein products for human meningococcemia (2003-07-22),

12. 6586400 - Human therapeutic uses of BPI protein products (2003-07-01),

13. 6583116 - Anti-chlamydial methods and materials (2003-06-24),

14. 6482796 - Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients (2002-11-19),

15. 6440936 - Anti-protozoan methods and materials (2002-08-27),

Xoma Corporation is a biotechnology company that focuses on the discovery and development of monoclonal antibody therapeutics. With a mission to advance human health, Xoma leverages its extensive experience in antibody biology and protein structure to create innovative therapies for a wide range of diseases. Through strategic collaborations and partnerships, Xoma aims to bring novel treatments to patients worldwide and make a positive impact on global healthcare.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

142 Patents

#1 in Berkeley, CA

#616 in California

#2,658 in US

#5,574 in the World

Berkeley, CA, United States of America

Xoma Corporation

Forward Citations = 4,462

76 inventors:

Roger G Little, Ii (25 out of 36 patents)

Stephen Fitzhugh Carroll (24 out of 30 patents)

Arnold H Horwitz (23 out of 49 patents)

4. Marc D Better (20 out of 29 patents)

5. Lewis H Lambert, Jr (16 out of 16 patents)

Please report any incorrect information to support@idiyas.com

Loading…